About Achieve Life Sciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://achievelifesciences.com/
Frequently Asked Questions
What is the 52-week range for ACHV?
The 52-week high is $8.64 and the 52-week low is $2.62.
What is the P/E ratio for ACHV?
The P/E ratio data is currently unavailable.
What is the dividend yield for ACHV?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -193.49%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -94.67%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 12.30.
Analyst Recommendation Trends
Wall Street analyst consensus for ACHV over the last few months:
Latest ACHV News
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisiniclineSEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjami
Achieve Life Sciences Appoints Benjamin Halladay CFO, Effective Oct. 5
Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine
Stifel Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $18
Stifel analyst James Condulis initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating and announces Price Target of $18.
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona. CHEST 2
Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade)
Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. Click for this ACHV stock update.
Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis
Achieve Life Sciences (ACHV) stock outlook: cytisinicline CRL tied to manufacturing compliance, cash runway to 2027, dilution risks & quit-smoking...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-19 | Stewart Richard Alistair | -20,626 | $8.493 | $175,177 |
| 2026-07-27 | Waldman Reid Alexander | +16,700 | - | - |
| 2026-07-27 | Waldman Reid Alexander | +25,000 | - | - |
| 2026-07-27 | Martin Christopher Nathan | +16,700 | - | - |
| 2026-07-27 | Martin Christopher Nathan | +25,000 | - | - |
| 2026-07-27 | Sellig Thomas | +16,700 | - | - |
| 2026-07-27 | Sellig Thomas | +25,000 | - | - |
| 2026-07-27 | Phelan Nancy R. | +16,700 | - | - |
| 2026-07-27 | Phelan Nancy R. | +25,000 | - | - |
| 2026-07-27 | Royston Aaron | +16,700 | - | - |
| 2026-07-27 | Royston Aaron | +25,000 | - | - |
| 2026-07-27 | Stewart Richard Alistair | +16,700 | - | - |
| 2026-07-27 | Stewart Richard Alistair | +25,000 | - | - |
| 2026-07-27 | Farrow Jeffrey S | +16,700 | - | - |
| 2026-07-27 | Farrow Jeffrey S | +25,000 | - | - |
| 2026-05-29 | Waldman Reid Alexander | +47,250 | - | - |
| 2026-05-29 | Farrow Jeffrey S | +47,250 | - | - |
| 2026-05-11 | Martin Christopher Nathan | +47,250 | - | - |
| 2026-04-18 | Goldberg Andrew D. | +11,706,270 | - | - |
| 2026-04-18 | Goldberg Andrew D. | +3,601,929 | - | - |
| 2026-04-18 | Goldberg Andrew D. | +1,800,965 | - | - |
| 2026-01-28 | Rubinstein Mark Lawrence | +180,000 | - | - |
| 2026-01-28 | Donnelly Craig | +180,000 | - | - |
| 2026-01-28 | Xinos Jaime | +180,000 | - | - |
| 2026-01-28 | Wan Jerry | +70,300 | - | - |
| 2026-01-28 | Stewart Richard Alistair | +645,000 | - | - |
| 2026-01-28 | Oki Mark K | +180,000 | - | - |
| 2025-12-04 | Atkisson Erik | +250,000 | - | - |